Ultraviolet A1 phototherapy for mycosis fungoides


  • Conflict of interest: none declared.

Dr Karolina Olek-Hrab, Department of Dermatology, Poznań University of Medical Science, 49 Przybyszewskiego, 60-355 Poznań, Poland
E-mail: k_hrab@go2.pl


Background.  Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative.

Aim.  To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1–T2).

Methods.  Four patients with early-stage MF were treated with 1630–2710 J/cm2 UVA1 given in 29–40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography.

Results.  Complete clinical remission of MF was achieved in all cases.

Conclusions.  This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF.